GEN Exclusives

More »

GEN News Highlights

Back to Item »

Chiva Nabs Chinese Rights to Ligand's Hep B and HCC Candidates

Use of Ligand’s HepDirect tech for the development of new candidates against hep B, hep C, and HCC part of deal.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

GEN Poll

More » Poll Results »

After Disney Measles Outbreak, Immunityland Less Magical

How should public health advocates counter anti-vaccination sentiment?